ASCO Data Could Clarify Ocular Toxicity Concerns For ImmunoGen’s Mirvetuximab
Pivotal Trial Results And Pooled Safety Analysis Being Presented
Executive Summary
ImmunoGen may need to mount an aggressive education campaign to get in front of issues like blurred vision and keratopathy, with ocular toxicity being common among antibody-drug conjugates.